Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
1745studies shown
Showing 1,249-1,260 of 1,745
Drug study icon
CompletedNCT00300846

Treatment of Aripiprazole for Schizophrenia

This study is completed in France, in the United Kingdom, in Switzerland, .... It is testing treatment of Aripiprazole for Schizophrenia.

In United Kingdom
SchizophreniaDrugA study involving a medication or substance.From 18 Years to 65 Years
Countries
France, United Kingdom, Switzerland, ...
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT05550532

Aticaprant 10 Milligrams (mg) for Depression

This study is completed in the United States, in France, in Canada, .... It is testing Aticaprant 10 Milligrams (mg) for Depression.

In United Kingdom
DepressionDrugFrom 18 Years to 74 Years
Countries
United States, France, Canada, ...
Sponsor
Janssen Research & Development, LLC
Condition
Depression
Drug study icon
CompletedNCT02006628

GWP42003 for schizophrenia

This study is completed in the United Kingdom, in Poland, and in Romania. It is testing GWP42003 for schizophrenia.

In United Kingdom
SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United Kingdom, Poland, Romania
Sponsor
Jazz Pharmaceuticals
Condition
Schizophrenia
Drug study icon
CompletedNCT04080752

JNJ-61393215 for depression

This study is completed in the United States, in the United Kingdom, in Moldova, .... It is testing JNJ-61393215 for depression.

In United Kingdom
DepressionDrugFrom 18 Years to 64 Years
Countries
United States, United Kingdom, Moldova, ...
Sponsor
Janssen Research & Development, LLC
Condition
Depression
Drug study icon
CompletedNCT05029401

Oral Ibogaine in Opioid Withdrawal

This study is completed in the United Kingdom. It is testing ibogaine for Addiction.

In United Kingdom
AddictionDrugFrom 18 Years to 55 Years
Countries
United Kingdom
Sponsor
atai Therapeutics, Inc.
Condition
Addiction
Drug study icon
TerminatedNCT00256997

Risperidone Long-Acting Injection Versus Oral Antipsychotics for schizophrenia

This study was terminated in Australia, in Canada, in the United Kingdom, .... It is testing Risperidone Long-Acting Injection Versus Oral Antipsychotics for schizophrenia.

In United Kingdom
SchizophreniaDrugFrom 18 Years to 65 Years
Countries
Australia, Canada, United Kingdom, ...
Sponsor
Janssen-Ortho Inc., Canada
Condition
Schizophrenia
Drug study icon
TerminatedNCT04951609

Seltorexant for depression

This study was terminated in the United States, in the United Kingdom, in Italy, .... It is testing seltorexant for depression.

In United Kingdom
DepressionDrugFrom 12 Years to 17 Years
Countries
United States, United Kingdom, Italy, ...
Sponsor
Janssen Research & Development, LLC
Condition
Depression
Drug study icon
CompletedNCT04513912

Seltorexant Compared to Quetiapine XR for depression

This study is completed in the United States, in Canada, in the United Kingdom, .... It is testing Seltorexant Compared to Quetiapine XR for depression.

In United Kingdom
DepressionDrugFrom 18 Years to 74 Years
Countries
United States, Canada, United Kingdom, ...
Sponsor
Janssen Research & Development, LLC
Condition
Depression
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.